1 / 26

How Do You Select Patients for EGFR-targeted Therapy?

How Do You Select Patients for EGFR-targeted Therapy?. Disclosure (Lee M. Ellis). EGF Receptor: Its Role in CRC Therapy. Selecting Patients for Anti-EGFR-Targeted Therapies in CRC. Selection of Patients for EGFR-Targeted Therapies B ased on EGFR- Positivity.

chidi
Download Presentation

How Do You Select Patients for EGFR-targeted Therapy?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. How Do You Select Patients for EGFR-targeted Therapy?

  2. Disclosure (Lee M. Ellis)

  3. EGF Receptor: Its Role in CRC Therapy

  4. Selecting Patients for Anti-EGFR-Targeted Therapies in CRC

  5. Selection of Patients for EGFR-TargetedTherapies Based on EGFR-Positivity

  6. Selecting Patients for Anti-EGFR-Targeted Therapies in CRC

  7. Bypass Pathways and EGFR Resistance

  8. KRAS Mutation as a Predictive Biomarker for EGFR MoAB Activity

  9. Single Agent Anti-EGFR Therapy /RAS Mutation Studies

  10. Wild-type KRAS is Required for PanitumumabEfficacy in Patients with Metastatic CRC

  11. Third-line PanitumumabvsBest Supportive Care: Impact of KRASMutations on PFS

  12. Effect of RAS Mutational Status on Growth Kinetics of Patients Treated with Cetuximab

  13. Chemotherapy Plus Anti-EGFR Therapy / RAS Mutation Studies

  14. KRAS Mutations as a Predictive Factor in Patients Treated with Cetuximab

  15. First-line Cetuximab in mCRC: Impact of KRAS Mutations in Patients Receiving Cetuximab (q2w) ± FOLFIRI

  16. Data from ASCO 2008

  17. FOLFOX4 ± Cetuximab as First-line Therapy of mCRC (OPUS): Effect of RAS Mutational Status

  18. Relationship of Efficacy and KRAS Status in Patients With Irinotecan- Refractory mCRC Treated With irinotecan and Escalating Doses of Cetuximab: The EVEREST Experience (Preliminary Data)

  19. Bypass Pathways and EGFR Resistance

  20. Loss of Expression of PTEN Predicts CetuximabEfficacy in Metastatic CRC

  21. Selecting Patients for Anti-EGFR-Targeted Therapies in CRC

  22. EGFR LigandsAmphiregulin / Epiregulin

  23. Epiregulin and Amphiregulin: Association with Response to CetuximabMonotherapy

  24. Epiregulin / Amphiregulin in KRAS Wild-type Patients Receiving Cetuximab + Irinotecan

  25. Biomarkers for EGFR-Targeted Therapies for mCRC

More Related